Claims
- 1. A method for determining the presence in an individual of a chromosomal aberration, wherein said aberration is selected from the group consisting of an inversion, a deletion/inversion, and a translocation, which comprises performing long distance, multiplex polymerase chain reaction utilizing a set of primers wherein said primers are selected from flanking regions of said aberration, wherein said polymerase chain reaction forms a first set of products when performed on a sample from an individual who lacks said aberration, said polymerase chain reaction forms a second set of products when performed on a sample from an individual who is homozygous or hemizygous for said aberration, and said polymerase gene forms a third set of products when performed on a sample from an individual who is heterozygous for said aberration, wherein if said first set of products is produced then said individual does not have said aberration, if said second set of products is produced then said individual is homozygous or hemizygous for said aberration, and if said third set of products is produced then said individual is heterozygous for said aberration.
- 2. The method of claim 1 wherein either
a) 3 primers are used; b) 4 primers are used; or c) more than 4 primers are used.
- 3. The method of claim 1 comprising overlapping PCR.
- 4. The method of claim 1 wherein said method produces at least one amplified product greater than 4 kilobases in length.
- 5. The method of claim 1 wherein said method produces at least one amplified product greater than 10 kilobases in length.
- 6. The method of claim 1 wherein said PCR comprises any combination of one, two or three of the following:
i) DMSO at a concentration of at least 6%; ii) DNA polymerase at a concentration of at least 0.05 units per μL; and iii) deaza-dGTP at a concentration of 33% or greater of the concentration of dGTP.
- 7. The method of claim 1 wherein
i) said PCR comprises two temperatures, ii) said PCR comprises three temperatures, or iii) said PCR comprises subcycling PCR.
- 8. The method of claim 1 wherein said PCR is performed in a single reaction vessel.
- 9. A method for screening for the presence of hemophilia A in a male wherein said method comprises performing long distance polymerase chain reaction (PCR) on a sample from said male using 2 primers, wherein said primers are specific for amplifying a region of an X chromosome comprising intron 22 of a factor VIII gene (Int22h1), wherein said method is performed under conditions which produce a PCR product when performed on a sample from a person who does not have hemophilia A, wherein the absence of a PCR product indicates the presence of hemophilia A in said male.
- 10. The method of claim 9 wherein one of said primers comprises SEQ ID NO: 8 and another of said primers comprises SEQ ID NO: 9.
- 11. A method for determining the presence of hemophilia A in a male or the presence in a female of an inversion comprising intron 22 of a factor VIII gene wherein said inversion results from a homologous recombination between Int22h1 and Int22h2 or Int22h3 and wherein said inversion results in hemophilia A when a person is hemizygous or homozygous for said inversion, wherein said method comprises performing long distance polymerase chain reaction on a sample from said male or said female using 2 primers, wherein a) a first primer is specific for a region upstream of Int22h1 and a second primer is specific for a region downstream of both Int22h2 and Int22h3 or b) a first primer is specific for a region upstream of both Int22h2 and Int22h3 and a second primer is specific for a region downstream of Int22h1, wherein the presence of a PCR product is indicative of hemophilia A in said male and is indicative of said female being a carrier of said inversion.
- 12. The method of claim 11 wherein said primers are selected from primers comprising a) SEQ ID NO: 8 and SEQ ID NO: 1, b) SEQ ID NO: 8 and bases 1-36 of SEQ ID NO: 11, or c) SEQ ID NO: 10 and SEQ ID NO: 9.
- 13. A method for screening for the presence of hemophilia A in a male or the absence of an inversion in either a male or the presence of said inversion in a female, wherein said inversion results from a homologous recombination between Int22h1 and Int22h2 or Int22h3 and wherein said inversion causes hemophilia A when present in a male, wherein said method comprises performing long distance, multiplex PCR on a sample from said male or from said female using 3 primers wherein a first primer is specific for an upstream region of Int22h1, a second primer is specific for a downstream region of Int22h1, and a third primer is specific for either an upstream or a downstream region of both Int22h2 and Int22h3, wherein amplification using said first primer and said second primer yields a PCR product of a first size and wherein amplification using said third primer and one of said second primer and said third primer yields a PCR product of a second size, wherein the presence of a PCR product of said first size is indicative that said male does not carry said inversion and wherein the presence of a PCR product of said second size is indicative that said male has hemophilia A or that said female is a carrier of said inversion.
- 14. The method of claim 13 wherein said first primer comprises SEQ ID NO: 8, b) said second primer comprises SEQ ID NO: 9 and c) said third primer is selected from the group consisting of a primer comprising SEQ ID NO: 10, a primer comprising SEQ ID NO: 11 and a primer comprising bases 1-36 of SEQ ID NO: 11.
- 15. A method for screening for the presence of hemophilia A in a male or the absence of an inversion in a male or the presence of said inversion in a female, wherein said inversion results from a homologous recombination between Int22h1 and Int22h2 or Int22h3 and wherein said inversion causes hemophilia A when present in a male, wherein said method comprises performing long distance, multiplex PCR on a sample from said male or from said female using 3 primers wherein a first primer is specific for both an upstream region of Int22h2 and an upstream region of Int22h3, a second primer is specific for both a downstream region of Int22h2 and a downstream region of Int22h3, and a third primer is specific for either an upstream or a downstream region of Int22h1, wherein amplification using said first primer and said second primer yields a PCR product of a first size and wherein amplification using said third primer and one of said first primer and said second primer yields a PCR product of a second size, wherein the presence of a PCR product of said second size in a sample from said male is indicative of the presence of hemophilia A in said male, the absence of a PCR product of said second size in a sample from said male is indicative of the absence of said inversion in said male, the presence of a PCR product of said second size in a sample from said female is indicative that said female is a carrier of said inversion, and the absence of a PCR product of said second size in a sample from said female is indicative that said female is not a carrier of said inversion.
- 16. The method of claim 15 wherein said first primer comprises SEQ ID NO: 10, b) said second primer comprises SEQ ID NO: 11 or bases 1-36 of SEQ ID NO: 11, and c) said third primer comprises SEQ ID NO: 8 or SEQ ID NO: 9.
- 17. A method for screening for the presence of hemophilia A in a male or the absence of an inversion in a male, wherein said inversion results from a homologous recombination between Int22h1 and Int22h2 or Int22h3 and wherein said inversion causes hemophilia A when present in a male, or to determine whether a female is a carrier of said inversion, wherein said method comprises performing long distance, multiplex PCR on a sample from said male or from said female using 4 or more primers wherein a first primer is specific for an upstream region of Int22h1, a second primer is specific for a downstream region of Int22h1, a third primer is specific for an upstream region of both Int22h2 and Int22h3, and a fourth primer is specific for a downstream region of both Int22h2 and Int22h3, wherein a PCR amplification product using said first primer and said second primer is a first size, a PCR amplification product using said third primer and said fourth primer is a second size, a PCR amplification product using said first primer and said fourth primer is a third size and a PCR amplification product using said second plimer and said third primer is a fourth size, wherein said first size and said second size may be equal to each other and wherein said third size and said fourth size may be equal to each other, wherein the presence of PCR amplification products of said first size and said second size in a sample from a male indicates the absence of said inversion in said male, the presence of PCR amplification products of said second size, said third size and said fourth size in a sample from a male indicates the presence of hemophilia A in said male, the presence of PCR amplification products of said first size and said second size and the absence of PCR amplification products of said third size and said fourth size in a sample from a female indicates the absence of said inversion in said female, and the presence of PCR amplification products of said first size, said second size, said third size and said fourth size from a sample from said female indicates that said female is a carrier of said inversion.
- 18. The method of claim 17 wherein said first primer comprises SEQ ID NO: 8, b) said second primer comprises SEQ ID NO: 9, c) said third primer comprises SEQ ID NO: 10, and d) said fourth primer comprises SEQ ID NO: 11 or bases 1-36 of SEQ ID NO: 11.
- 19. The method of claim 9 wherein said PCR comprises any combination of one, two or three of the following:
i) DMSO at a concentration of at least 6%; ii) DNA polymerase at a concentration of at least 0.05 units per μL; and iii) a concentration of deaza-dGTP and a concentration of dGTP wherein said concentration of deaza-dGTP is greater than or equal to 33% of said concentration of dGTP.
- 20. The method of claim 11 wherein said PCR comprises any combination of one, two or three of the following:
i) DMSO at a concentration of at least 6%; ii) DNA polymerase at a concentration of at least 0.05 units per μL; and iii) a concentration of deaza-dGTP and a concentration of dGTP wherein said concentration of deaza-dGTP is greater than or equal to 33% of said concentration of dGTP.
- 21. The method of claim 13 wherein said PCR comprises any combination of one, two or three of the following:
i) DMSO at a concentration of at least 6%; ii) DNA polymerase at a concentration of at least 0.05 units per μL; and iii) a concentration of deaza-dGTP and a concentration of dGTP wherein said concentration of deaza-dGTP is greater than or equal to 33% of said concentration of dGTP.
- 22. The method of claim 15 wherein said PCR comprises any combination of one, two or three of the following:
i) DMSO at a concentration of at least 6%; ii) DNA polymerase at a concentration of at least 0.05 units per μL; and iii) a concentration of deaza-dGTP and a concentration of dGTP wherein said concentration of deaza-dGTP is greater than or equal to 33% of said concentration of dGTP.
- 23. The method of claim 17 wherein said PCR comprises any combination of one, two or three of the following:
i) DMSO at a concentration of at least 6%; ii) DNA polymerase at a concentration of at least 0.05 units per μL; and iii) a concentration of deaza-dGTP and a concentration of dGTP wherein said concentration of deaza-dGTP is greater than or equal to 33% of said concentration of dGTP.
- 24. The method of claim 9 wherein
i) said PCR comprises two temperatures, ii) said PCR comprises three temperatures, or iii) said PCR comprises subcycling PCR.
- 25. The method of claim 11 wherein
i) said PCR comprises two temperatures, ii) said PCR comprises three temperatures, or iii) said PCR comprises subcycling PCR.
- 26. The method of claim 13 wherein
i) said PCR comprises two temperatures, ii) said PCR comprises three temperatures, or iii) said PCR comprises subcycling PCR.
- 27. The method of claim 15 wherein
i) said PCR comprises two temperatures, ii) said PCR comprises three temperatures, or iii) said PCR comprises subcycling PCR.
- 28. The method of claim 17 wherein
i) said PCR comprises two temperatures, ii) said PCR comprises three temperatures, or iii) said PCR comprises subcycling PCR.
- 29. The method of claim 13 wherein said PCR is performed in a single reaction vessel.
- 30. The method of claim 15 wherein said PCR is performed in a single reaction vessel.
- 31. The method of claim 17 wherein said PCR is performed in a single reaction vessel.
- 32. A method for performing a polymerase chain reaction (PCR) wherein said PCR comprises cycling the temperature between a step of annealing/elongation and a step of denaturation and wherein said step of annealing/elongation and said step of denaturation are performed at different temperatures from each other and wherein each cycle of PCR comprises a step of denaturation, and further wherein said step of annealing/elongation comprises steps of temperature subcycling wherein said temperature is varied betwecn m temperatures of subcycling, wherein m≧2, for at least n subcycles, wherein n≧1, and wherein m times n≧3, for each cycle of PCR wherein said temperatures of subcycling are lower than a temperature required to denature desired PCR products.
- 33. The method of claim 32 wherein said annealing/elongation step is performed at at least three temperatures wherein an annealing step is performed at one temperature and an elongation step is performed at at least two temperatures and wherein said subcycling is performed for said elongation step.
- 34. The method of claim 32 wherein said temperature of subcycling are in the range from 50° C. to 75° C.
- 35. The method of claim 32 wherein said subcycling is continuous wherein said temperature is constantly changed during said subcycling without holding the temperature at a single temperature.
- 36. The method of claim 32 wherein said temperature may be held at any one or more temperatures for a period of time prior to subcycling to another temperature.
- 37. The method of claim 36 whercin said temperature may be held for different periods of time for different temperatures during said subcycling.
- 38. The method of claim 36 wherein said temperature may be held at a same temperature for different periods of time during different subcycles.
- 39. The method of claim 32 wherein said subcycling begins at a high temperature of subcycling followed by a low temperature of subcycling.
- 40. The method of claim 32 wherein said subcycling begins at a low temperature of subcycling followed by a high temperature of subcycling.
- 41. The method of claim 32 wherein one subcycle is performed for a different length of time as compared to another subcycle.
- 42. The method of claim 32 wherein said PCR is performed with at least three primers.
- 43. The method of claim 33 wherein said PCR is performed with at least three primers.
- 44. The method of claim 32 comprising long distance PCR.
- 45. The method of claim 32 comprising multiplex, long distance PCR.
- 46. The method of claim 32 comprising long distance, overlapping PCR.
- 47. The method of claim 32 comprising random PCR.
- 48. The method of claim 32 wherein said PCR is performed on a template comprising a first region with a GC content of X percent and a second region with a GC content of Y percent wherein each of said regions is a minimum of 100 base pairs in length and wherein the absolute value of X minus Y is greater than or equal to 20.
- 49. The method of claim 32 comprising two different DNA polymerases.
- 50. The method of claim 49 wherein said DNA polymerases are selected from the group consisting of Taq, Pwo, Vent, Tth and Tfl.
- 51. The method of claim 49 wherein said DNA polymerases are selected from the group of the pairs: Taq/Pwo, Taq/Vent, Tth/Pwo, Tth/Vent, Tfl/Pwo and Tfl/Vent.
- 52. The method of claim 49 wherein the two DNA polymerases are at a ratio of 30:1 (units:units).
- 53. A nucleic acid comprising at least 13 consecutive bases of a DNA sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 and bases 1-36 of SEQ ID NO: 11.
- 54. A nucleic acid of claim 53 wherein said DNA sequence is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 4 and SEQ ID NO: 5.
- 55. A nucleic acid of claim 53 wherein said DNA sequence is selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 6 and SEQ ID NO: 7.
- 56. A nucleic acid of claim 53 wherein said DNA sequence is selected from the group consisting of SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 and bases 1-36 of SEQ ID NO: 11.
- 57. A nucleic acid consisting of a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 and bases 1-36 of SEQ ID NO: 11.
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] The present invention is a continuation-in-part of application Ser. No. 09/103,505 filed Jun. 24, 1998.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60113669 |
Jun 1998 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09200934 |
Nov 1998 |
US |
Child |
10013718 |
Dec 2001 |
US |